CTLA4 and neoplasm: Interestingly, a recent study demonstrated that TNFα inhibitors concomitantly with combined anti-PD-1 and anti-CTLA-4 antibodies improved immune related colitis in addition to enhanced anti-tumor efficacy [27,28].